Molecular Formula | C19H16N2O2
|
Molar Mass | 304.34 |
Density | 1.24±0.1 g/cm3(Predicted) |
Melting Point | 110-112℃ |
Boling Point | 522.2±50.0 °C(Predicted) |
Solubility | DMSO: 12mg/mL |
Appearance | solid |
Color | white |
pKa | 13.83±0.10(Predicted) |
Storage Condition | Sealed in dry,Room Temperature |
Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months. |
In vitro study | YC-1 is an allosteric activator of soluble guanylate cyclase (sGC). YC-1 enhances the catalytic rate of the enzyme and sensitizes sGC to nitric oxide gas activators or carbon monoxide. YC-1 alone can only activate sGC 10 times, it can enhance the activation efficiency of sGC dependent on CO and NO, resulting in the activation of highly purified enzyme, which can be hundreds to thousands of times more effective. In Vitro, YC-1 inhibits platelet aggregation, vasoconstriction and HIF-1 activity. YC-1 can completely inhibit the expression of HIF-1α at the post-transcriptional level, thus inhibiting the activity of HIF-1 transcription factors in liver cancer cells under hypoxic conditions, indicating that the role of YC-1 may be related to the oxygen sensing pathway, rather than sGC related. |
In vivo study | The application of YC-1 to experimental animals resulted in inhibition of platelet-rich thrombosis and a decrease in mean arterial blood pressure (associated with an increase in cGMP levels). YC-1 can effectively inhibit tumor growth in tumor-negative mice. Inhibition of HIF-1 activity in YC-1-treated mouse tumors correlates with inhibition of angiogenesis, tumor growth. The antiplatelet effect of YC-1 does not affect tumor growth. |